Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.39 |
| ▸ | MPL | P40238 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18022312 | 0.83 | KCNMA1 (0.71) | KCNMA1ADRA2ACLCN2KDM4EPIM1 | |
| SCHEMBL2925491 | 0.81 | KCNMA1 (0.68) | KCNMA1ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL2933540 | 0.81 | KCNMA1 (0.67) | KCNMA1ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL2925140 | 0.76 | KCNMA1 (0.61) | KCNMA1HSD17B10PIM1PIM2MEN1 | |
| SCHEMBL2931881 | 0.73 | KCNMA1 (0.57) | KCNMA1PIM1PIM2CSNK2A2CSNK2B | |
| SCHEMBL2932784 | 0.72 | KCNMA1 (0.57) | KCNMA1ALDH1A1PIM1PIM2PBRM1 | |
| SCHEMBL17536384 | 0.71 | KCNMA1 (0.55) | KCNMA1ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL2931043 | 0.68 | KCNMA1 (0.52) | KCNMA1ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL2931271 | 0.68 | KCNMA1 (0.50) | KCNMA1KDM4EMEN1KMT2A | |
| SCHEMBL78221 | 0.67 | MRGPRX4 (0.61) | KCNMA1ALDH1A1HPGDKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021303-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | CANBEX THERAPEUTICS LTD (GB) | 2018-01-25 | — | — | US | claimed |
| EP-3256122-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | Canbex Therapeutics Limited (GB) | 2017-12-20 | — | — | EP | claimed |
| US-20160235710-A1 | COMPOSITION FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION COMPRISING LDD175 AS ACTIVE INGREDIENT | SNU R&D FOUNDATION (KR) | 2016-08-18 | — | — | US | claimed |
| WO-2016128772-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | claimed |
| US-11517556-B2 | Composition for BKCa channel activation | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-06 | — | — | US | disclosed |
| WO-2022075780-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OVERACTIVE BLADDER | 광주과학기술원 | 2022-04-14 | — | — | WO | disclosed |
| US-20200069640-A1 | COMPOSITION FOR BKCA CHANNEL ACTIVATION | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-03-05 | — | — | US | disclosed |
| US-20190083456-A1 | COMPOSITION FOR BKCA CHANNEL ACTIVATION | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2019-03-21 | — | — | US | disclosed |
| US-20180021303-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | CANBEX THERAPEUTICS LTD (GB) | 2018-01-25 | — | — | US | disclosed |
| EP-3256122-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | Canbex Therapeutics Limited (GB) | 2017-12-20 | — | — | EP | disclosed |
| WO-2017160128-A1 | COMPOSITION FOR ACTIVATION OF BKCA CHANNELS | 광주과학기술원 | 2017-09-21 | — | — | WO | disclosed |
| US-20160235710-A1 | COMPOSITION FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION COMPRISING LDD175 AS ACTIVE INGREDIENT | SNU R&D FOUNDATION (KR) | 2016-08-18 | — | — | US | disclosed |
| WO-2016128772-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| US-20160061816-A1 | SCREENING METHOD FOR ION CHANNEL MODULATORS USING MUTATED BKCA CHANNEL | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-03-03 | — | — | US | disclosed |
| US-7812177-B2 | Potassium channel opener having benzofuroindole skeleton | ANYGEN CO., LTD. (KR) | 2010-10-12 | — | — | US | disclosed |
| EP-1861092-B1 | POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON | ANYGEN CO LTD (KR) | 2010-09-15 | — | — | EP | disclosed |
| EP-1861092-A4 | POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON | ANYGEN CO LTD (KR) | 2009-04-15 | — | — | EP | disclosed |
| US-20080194837-A1 | Potassium Channel Opener Having Benzofuroindole Skeleton | ANYGEN CO., LTD. (KR) | 2008-08-14 | — | — | US | disclosed |
| EP-1861092-A1 | POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON | Anygen Co., Ltd. (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006096030-A1 | POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON | ANYGEN CO., LTD. (KR) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069640-A1 | COMPOSITION FOR BKCA CHANNEL ACTIVATION | KCNAB1, KCNN3, KCNC1 | KCNMA1 8/4885ADRA2A 534/4885CLCN2 150/4885 |
| US-20180021303-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | KCNMA1, KCNMB1, KCNA1 | KCNMA1 1/4885ADRA2A 777/4885CLCN2 261/4885 |
| US-11517556-B2 | Composition for BKCa channel activation | KCNAB1, KCNN3, KCNC1 | KCNMA1 8/4885ADRA2A 534/4885CLCN2 150/4885 |
| US-20160235710-A1 | COMPOSITION FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION COMPRISING LDD175 AS ACTIVE INGREDIENT | PDE5A, PDE3A, PDE2A | KCNMA1 56/4885ADRA2A 227/4885CLCN2 1138/4885 |
| US-20080194837-A1 | Potassium Channel Opener Having Benzofuroindole Skeleton | KCNJ2, KCNN3, KCNH2 | KCNMA1 41/4885ADRA2A 1109/4885CLCN2 85/4885 |
| US-20190083456-A1 | COMPOSITION FOR BKCA CHANNEL ACTIVATION | KCNAB1, KCNN3, KCNC1 | KCNMA1 8/4885ADRA2A 534/4885CLCN2 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.